Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1947 1
1949 1
1950 3
1953 1
1954 3
1955 2
1956 2
1957 1
1959 6
1961 1
1962 3
1963 2
1964 3
1965 3
1966 2
1967 1
1968 3
1970 3
1971 5
1972 1
1973 1
1974 4
1975 4
1976 4
1977 2
1978 3
1980 1
1981 1
1983 3
1984 1
1985 1
1986 1
1987 3
1988 1
1989 1
1990 3
1992 1
1993 1
1994 2
1995 3
1996 6
1997 5
1998 6
1999 3
2000 14
2001 15
2002 14
2003 19
2004 14
2005 19
2006 28
2007 17
2008 22
2009 18
2010 17
2011 18
2012 37
2013 31
2014 17
2015 29
2016 25
2017 33
2018 34
2019 30
2020 29
2021 49
2022 39
2023 26
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

650 results

Results by year

Filters applied: . Clear all
Page 1
Precocious puberty.
Bradley SH, Lawrence N, Steele C, Mohamed Z. Bradley SH, et al. Among authors: lawrence n. BMJ. 2020 Jan 13;368:l6597. doi: 10.1136/bmj.l6597. BMJ. 2020. PMID: 31932347 Review. No abstract available.
Sebaceous carcinoma: evidence-based clinical practice guidelines.
Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS, Bradshaw SH, Cartee TV, Chandra S, Cho NL, Choi JN, Council ML, Demirci H, Eisen DB, Esmaeli B, Golda N, Huang CC, Ibrahim SF, Jiang SB, Kim J, Kuzel TM, Lai SY, Lawrence N, Lee EH, Leitenberger JJ, Maher IA, Mann MW, Minkis K, Mittal BB, Nehal KS, Neuhaus IM, Ozog DM, Petersen B, Rotemberg V, Samant S, Samie FH, Servaes S, Shields CL, Shin TM, Sobanko JF, Somani AK, Stebbins WG, Thomas JR, Thomas VD, Tse DT, Waldman AH, Wong MK, Xu YG, Yu SS, Zeitouni NC, Ramsay T, Reynolds KA, Poon E, Alam M. Owen JL, et al. Among authors: lawrence n. Lancet Oncol. 2019 Dec;20(12):e699-e714. doi: 10.1016/S1470-2045(19)30673-4. Lancet Oncol. 2019. PMID: 31797796 Review.
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, Chung KY, Cliby WA, Dorigo O, Eisen DB, Fujisawa Y, Golda N, Halfdanarson TR, Iavazzo C, Jiang SIB, Kanitakis J, Khan A, Kim JYS, Kuzel TM, Lawrence N, Leitao MM Jr, MacLean AB, Maher IA, Mittal BB, Nehal KS, Ozog DM, Pettaway CA, Ross JS, Rossi AM, Servaes S, Solomon MJ, Thomas VD, Tolia M, Voelzke BB, Waldman A, Wong MK, Zhou Y, Arai N, Brackett A, Ibrahim SA, Kang BY, Poon E, Alam M. Kibbi N, et al. Among authors: lawrence n. JAMA Oncol. 2022 Apr 1;8(4):618-628. doi: 10.1001/jamaoncol.2021.7148. JAMA Oncol. 2022. PMID: 35050310
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. Among authors: lawrence nj. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: lawrence nj. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Male Body Contouring.
Coleman KM, Lawrence N. Coleman KM, et al. Among authors: lawrence n. Dermatol Surg. 2017 Nov;43 Suppl 2:S188-S193. doi: 10.1097/DSS.0000000000001319. Dermatol Surg. 2017. PMID: 28858933 Review.
Decision-making with uncertainty.
Diggle PJ, Gowers T, Kelly F, Lawrence N. Diggle PJ, et al. Among authors: lawrence n. Signif (Oxf). 2020 Dec;17(6):12. doi: 10.1111/1740-9713.01463. Epub 2020 Dec 2. Signif (Oxf). 2020. PMID: 33362874 Free PMC article.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team; Davis ID. Hofman MS, et al. Among authors: lawrence nj. BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22. BJU Int. 2019. PMID: 31638341 Free article. Clinical Trial.
650 results